Showing 9 results for Tabatabaei
Mahnaz Lankarani, Fatemeh Bandarian, Ozra Tabatabaei, Mohammad Pajouhi, Bagher Larijani,
Volume 4, Issue 1 (17 2004)
Abstract
Background: Gliclazide is a second generation sulfonylurea which its efficacy and safety in the treatment of diabetes has been established. Diamicron MR (30 mg) is a new formulation of gliclazide with modified release which offer once daily dosage administration. This study was designed to assess the effect of combination therapy with diamicron and metformin in the treatment of type 2 diabetes.
Methods: 16 patients with type 2 diabetes (2 males, 14 females) more than 35 years old who despite treatment with glibenclamide and metformin had poor diabetes control participated in this clinical trial.HbA1c, lipid profile, liver and renal function tests at the end of study were compared with before.
Results: No significant changes was found in FBS, BS2hpp, lipid profile and renal and liver function tests at the end of study. Patients' weight was stable during the study.
Conclusion: Regardless of well efficacy of diamicron in the treatment of new diabetics cases, it is not recommended for patients with poor diabetes control despite of combination therapy with metformin and glibenclamide.
Azamsadat Tabatabaei, Negar Horri, Mahboubeh Farmani, Sasan Haghighi, Badrolmolouk Forghani, Masoud Amini,
Volume 4, Issue 2 (17 2004)
Abstract
Background: Constipation is the most common gastrointestinal complication in diabetic patients. Erythromycin mimics the effects of the gastrointestinal hormone Motilin in gastric contractile activity and insulin secretion. In this study, we compared the effects of Erythromycin and Metoclopramide on glycemic control and constipation in type 2 diabetic patients.
Methods: As a clinical trial, thirty-nine type 2 diabetic patients with constipation were divided into two groups. Patients in group 1 (n=24) were treated with erythromycin (400 mg/day before sleep) and participants in the second group (n=15) received metoclopramide (10mg 3 times / day before each meal) for 3 months. FBS, 2hPP BS, HbA1c and the frequency of defecations during a week were measured and compared before and after the intervention.
Results: In Erythromycin treated group, 2hPP BS decreased from 199.7 ± 47.0 before treatment to 174.0±46.3 after intervention (P=0.01) and a significant improvement in constipational symptoms was observed in both groups.
Conclusion: It seems that Erythromycin not only can improve symptoms of constipation but may have a role in glycemic control in type 2 diabetic patients.
Farid Abolhasani, Mohammad Reza Mohagerie Tehrani, Ozra Tabatabaei, Bagher Larijani,
Volume 5, Issue 1 (18 2005)
Abstract
Background: Since by considering increases worldwide prevalence of diabetes mellitus, and its management in the short and long–term requires significant expenditure on the part of patients and healthcare providers alike, and on the other hand existing resources fall short of the country's needs in this domain, diabetes has become one of the major health priorities in our country, as it has across the globe. Assessment of injuries due to diabetes mellitus and complications are divided to two sections: 1– economic cost of diabetes mellitus and 2 – burden of diabetes mellitus. In this study we assessed burden of diabetes mellitus and complications in Iran in year 2000.
Methods: We used ten years ago studies about prevalence of diabetes and complications in Iran, associated DALYs index by helping computer model (DisMod) for assessment of burden of diabetes and complications in Iran in year 2000.
Results: Burden of diabetes in Iran was 306440 years in year 2000. Burden of diabetic retinopathy, nephropathy, neuropathy, diabetic foot and lower limb amputation were 20532, 20532, 33286, 5848 and 1573 years, respectively.
Conclusion: Pay attention to this study, we will need to reduce diabetes's burden by setting serious programs about prevention and treatment of diabetes mellitus and complications. Thus, we suggest, other studies are planning for assessment of burden of other diseases. Then after comparing burden of diabetes to other diseases, government politicians are performance priorities setting for using of our country resource.
Ozra Tabatabaei Malazy, Ramin Heshmat, Seyed Akhavan Hejazy Mogaddam Sa, Eghbal Taheri, Seddigheh Soheilykhah, Farzaneh Darvishzadeh, Bagher Larijani,
Volume 5, Issue 1 (18 2005)
Abstract
Background: Metformin is usually using for glycemic control in type 2 diabetes mellitus. The drug is the first line for obese patients without renal or liver failure. Different pharmaceutical types of Metformin are available. As a clinical trial, we compared effects of Aria Metformin (product of Aria pharmaceutical company, Iran) with Merck Metformin or Glucophage (product of Merck pharmaceutical company, France), in diabetic patients.
Methods: This double blind randomized clinical trial study performed with 60 non- pregnant diabetic patients, in order to comparison of therapeutic effects of combination therapy (Glibenclamide + Metformin "Aria or Merck") in a 12 weeks period. We evaluated FBS, BS 2hpp, HbA1c, lipid profile, liver function tests, weight, BMI and common or uncommon side effects.
Results: Not only each of two pharmaceutical types of Metformin had the same therapeutic effects for controlling of glycemia, lipid profile and weight, but also there were not difference between them in side effects. Distention was the most common side effects of two types products (33%). There is not significant difference between them in common side effects. 70% of patients were satisfied with each two kinds of Metformin.
Conclusion: It seems, in view of beneficial therapeutic effects of Aria Metformin, low rate of side effects, and finally low cost, Aria Metformin is a good choice.
Ozra Tabatabaei Malazy, Mohammad Reza Mohajeri Tehrani, Mohammad Hossein Forozanfar, Zahra Shaban Nejad, Bagher Larijani,
Volume 6, Issue 4 (17 2007)
Abstract
Background: Pump therapy (CSII) is offered as a safe and effective treatment for patients with type 1 Diabetes. We examined the efficacy and safety of continuous subcutaneous Insulin Infusion Therapy for six months as a before-after clinical trial study among type 1 diabetic patients. This is the first survey of this experience in Iranian patients.
Methods: We recruited, type 1 diabetic patients without chronic complications of diabetes (retinopathy, nephropathy and etc.) and followed them for six months as a before-after clinical study with use of the pump. The efficacy of this way was assessed with HbA1C and fasting blood sugar measurements. Safety was estimated by frequency of clinical hypoglycemia episodes.
Results: Our patients were 7 men and 2 women aged 15 - 39 years with past history of diabetes by ranging from 0.1 to 15 years. Mean level of HbA1C at the beginning of study and after six months follow-up were %8.6 and %7.1, respectively, with significant statistically difference between them (P= 0.02). During pump therapy the mean dose of insulin were decreased to 10 units with statistically significant difference to before investigation (P = 0.03). No case of hypoglycemia and weight loss was seen. One patient had 4 kg weight gain without any significant statistical effect.
Conclusion: It seems CSII Therapy in Iranian patients with type 1 Diabetes mellitus was effective and safe. We can not conclude about possible side effects of pump based on this study.
Abolfazl Mohammad Beigi, Hamidreza Tabatabaei, Bahram Zeighami, Narges Mohammad Salehi,
Volume 7, Issue 1 (18 2007)
Abstract
Background: Glucose metabolism impairment may occur during some pregnancies especially of advanced age and history of previous gestational diabetes and may result in hazardous consequences both for mother and neonate.
Methods: The present study as a case-control was conducted on 420 referred pregnant women to Shiraz hospitals that involve 70 diabetic patients and 350 non-diabetic women. Data analyzed by analysis of variance and χ square for univariate and logistic regression for multivariate analysis.
Results: From 70 diabetic patients 22(31.4%) afflicted with overt diabetes as well as 48 (68.6%) gestational diabetes. Gestational diabetes history (OR=23.14), hydramnious (OR=13.26), glucosuria at 3rd trimester (OR=11.49), family history of diabetes (OR=4.09) and age (OR=1.03) were the most important risk factors for gestational diabetes, respectively. History of macrosomia in previous pregnancies (OR=18.83) and history of previous cesarean section (OR=11.96) were the most important predictors for overt diabetes.
Conclusion: In view of several threatening consequences of diabetes during pregnancy, screening for diabetes especially in mothers with gestational diabetes history and family history of diabetes is essential in order to control and prevention of these outcomes in mother and neonate.
Oussama Khatib, Ozra Tabatabaei Malazy,
Volume 7, Issue 2 (17 2007)
Abstract
Diabetes among Eastern Mediterranean (EM) population above age of 20 years is around 10.5% and is ranked among the leading causes of blindness, renal failure and lower limb amputation. While 50% of EM people with diabetes will die of cardiovascular diseases. This means that in our region, there are pandemic trends in prevalence of diabetes and associated complications. Globally, people with diabetes are 25 times more likely to have a leg amputated than those without the condition, and up to 70% of all leg amputations happen to people with diabetes. Somewhere in the world, a leg is lost to diabetes every 30 seconds. Foot ulcer is the most common single precursor to lower extremity amputations among diabetics. Hyperglycemia, impaired immunologic responses, neuropathy, and peripheral arterial disease are the major predisposing factors leading to limb-threatening diabetic foot infections. Diabetic foot represents a health problem and economic burden among majority of EM Countries. Infection in a diabetic foot is limb-threatening and must be treated empirically and aggressively. Treatment of infected foot wounds is the most common reason for diabetes- related hospitalization. The good news is that up to 85 percent of diabetic amputations can be prevented. As to above challenge, the best approach for EMR is education, community awareness and prevention of diabetic foot. The public approach and education that emphasize on proper footwear and foot care are best preventive and cost-effective modalities that can be easily implemented among EM Countries. EM Countries need to strengthen national health services that promote the concept of prevention and tight control of diabetes in order to prevention diabetes complications. This also necessitates building/strengthening diabetes registry and complications.
Sina Azadnajafabad, Sahar Saeedi Moghaddam, Esmaeil Mohammadi, Negar Rezaei, Nazila Rezaei, Shohreh Naderimagham, Rosa Haghshenas, Erfan Ghasemi, Yosef Farzi, Elham Abdolhamidi, Sahar Mohammadi Fateh, Hossein Zokaei, Ameneh Kazemi, Ozra Tabatabaei-Malazy, Farshad Farzadfar, Bagher Larijani,
Volume 20, Issue 1 (25th Anniversary of the Foundation, Special Issue 2021)
Abstract
Non-Communicable Diseases (NCDs) are the major cause of premature death and disability due to diseased globally, imposing a heavy burden on the health systems. Four main categories of NCDs are cardiovascular diseases, neoplasms, diabetes, and chronic respiratory diseases. Iran, the second greatest country in the Middle East Region, has been through an important transition period of communicable diseases toward NCDs in the last decades. One of the effective approaches to control NCDs is implementation of population-based studies and interventions, trying to reduce risk factors and incidence of NCDs through investigations in the populations. Endocrinology and Metabolism Research Institute (EMRI) and Non-Communicable Diseases Research Center (NCDRC) are the pioneers trying to study and control various NCDs during the last decades in Iran. In this review, we are going to inspect some of the major completed and ongoing projects of this research institute to highlight valuable efforts to reduce burden of NCDs in Iran, and make a successful example for national and regional public health policy makers and authorities.
Mahboobeh Rangraz Tabatabaei, Masoud Nikbakht, Rohollah Ranjbar, Farhad Daryanoosh, Mohsen Ghanbarzadeh,
Volume 23, Issue 1 (5-2023)
Abstract
Background: The release of adipokines from adipose tissue depots plays a key role in regulating metabolic homeostasis and several other physiological processes, including diabetes, obesity, and vascular diseases. This study investigated the effect of eight weeks of high intensity interval training (HIIT) on asprosin, lipid profile and insulin resistance in type 2 diabetic male rats.
Methods: 24 male Sprague Dawley rats were randomly divided into four equal groups: control (C), control traning (C+T), diabet (D) and diabet traning (D+T). Diabetes was induced by the combined method of high fat diet and low dose strepotozocin injection. The traning group performed the HIIT program on the treadmill for eight weeks. Data were analyzed using one-way ANOVA and bonferroni post hoc test at a significance level of P<0.05.
Results: The results showed increased plasma asprosin in D group compared to C (P=0.0001) and decreased in C+T group compared to C (P=0.03) and D+T group compared to D (P=0.04). There was no significant difference in HOMA-IR between the C and C+T group (P=0.9) but decreased in D+T compared to D (P=0.0001). HDL increased in D+T group compared to the D (P=0.0001) and decreased TG and LDL (P=0.001). There was no significant difference between TG and LDL in the C group compared to the C+T, but HDL increased in C+T (P=0.01).
Conclusion: Plasma asprosin increases in rats with type 2 diabetes and HIIT can reduce the complications of diabetes by improved lipid profile and reduce asprosin and insulin resistance.
